Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Reported Saturday, Organon Presents Real-World Data At ACR Showing 1.3% Switchback Rate After Over 16,000 US Veterans Switched From HUMIRA To HADLIMA
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Organon To Present New Analysis Of Phase 3 Data Evaluating VTAMA Cream In Patients With Atopic Dermatitis, At 2026 ACAAI Annual Scientific Meeting
Organon (OGN) Q3 Results Highlight A Thin Margin Cushion
Organon: Q3 Earnings Snapshot
Organon Announces Quarterly Dividend
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older
Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis
Why Organon (OGN) Is Getting Attention Today
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.